G2082 Insurance Policy Changes

HCPCS G2082 is officially defined as "Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation." HCPCS G2082 is referenced in 4 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi, Connecticut Medicaid (HUSKY Health), and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G2082 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.